Xingya Li

机构：Second Affiliated Hospital of Zhengzhou University, First Affiliated Hospital of Zhengzhou University · ORCID：0000-0002-8265-7318

发表论文 182 篇 · 总被引 6272 次 · h-index 36

代表论文

• Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China (2025 · The Lancet · 被引 150)
• Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial (2024 · Nature Medicine · 被引 128)
• Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study (2025 · The Lancet Oncology · 被引 49)
• Sacituzumab tirumotecan versus docetaxel for previously treated EGFR -mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial (2025 · BMJ · 被引 41)
• Vebreltinib for Advanced Non–Small Cell Lung Cancer Harboring c-Met Exon 14 Skipping Mutation: A Multicenter, Single-Arm, Phase II KUNPENG Study (2024 · Journal of Clinical Oncology · 被引 34)
• The antibody–drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial (2025 · Nature Medicine · 被引 21)